Key points:
- Vaxcyte announced VAX-24 met primary safety and tolerability objectives
- VAX-24 demonstrated a safety profile similar to Pfizer’s Prevnar 20
- Vaxcyte shares surged 57% premarket
Shares of California-based Vaxcyte, Inc (NASDAQ: PCVX) surged over 57% Monday morning after the company said its investigational 24-valent pneumococcal conjugate vaccine (PCV), VAX-24 met the primary safety and tolerability objectives.
The biotechnology company said VAX-24 demonstrated a safety profile similar to Pfizer’s Prevnar 20 for all doses studied.
The Phase 1/2 clinical proof-of-concept study evaluated the safety, tolerability, and immunogenicity of VAX-24, with all 24 Serotypes of VAX-24 at the conventional 2.2mcg PCV dose meeting or exceeding regulatory immunogenicity standards.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Also Read: Five Best Pharmaceutical Stocks To Watch In 2022
“At this dose, VAX-24 met the standard opsonophagocytic activity (OPA) response non-inferiority criteria for all 20 serotypes common with PCV20, of which 16 achieved higher immune responses,” the company added.
Vaxcyte said it now intends to progress VAX-24 into a Phase 3 program.
Vaxcyte shares are currently trading at $32.35 following the over 57% jump. On Friday, the stock fell over 7%, closing the session at $20.58, putting it down over 13% in 2022.
“We are thrilled with these positive topline results from our Phase 1/2 proof-of-concept study, which met all of our objectives. The findings indicate a potential best-in-class profile for VAX-24 and validate our carrier-sparing approach to enable the development of broader-spectrum PCVs,” said Grant Pickering, Chief Executive Officer and Co-Founder of Vaxcyte.
“The study results demonstrate that VAX-24 has the potential to provide broader coverage and better immune responses relative to the standard-of-care. We believe this presents an opportunity to set a new bar for immunogenicity standards for pneumococcal vaccines.”
